Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0VYVPF
ADC Name
Her3-C3-ADC-21 (DAR8)
Synonyms
Her3 C3 ADC 21 (DAR8)
   Click to Show/Hide
Organization
Suzhou Medilink Therapeutics Ltd.
Drug Status
Investigative
Indication
In total 2 Indication(s)
Colon cancer [ICD11:2B90]
Investigative
Lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
9.5
Antibody Name
Her3-C3
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-3 (ERBB3)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Her3-C3-ADC-21(DAR8) linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 44
%
SW480 cells
Colon adenocarcinoma
Tumor Growth Inhibition value (TGI) 
≈ 92.64
%
SW480 cells
Colon adenocarcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 44.00% (Day 15) Positive CD276 expression (CD276 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 3 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model SW480 CDX model
In Vitro Model Colon adenocarcinoma SW480 cells CVCL_0546
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 92.64% (Day 15) Positive CD276 expression (CD276 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established xenograft model of SW480 cells implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 10 mg/kg, i.v., QW*3 of one of the conjugates listed above or with PBS only.
In Vivo Model SW480 CDX model
In Vitro Model Colon adenocarcinoma SW480 cells CVCL_0546
References
Ref 1 Bioactive substance conjugate, preparation method therefor and use thereof; 2022-08-18.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.